Adimmune Corp. | Balance Sheet

Fiscal year is January-December. All values TWD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
515
1,017
943
1,674
1,235
649
Total Accounts Receivable
171
207
23
402
42
438
Inventories
305
372
494
508
638
491
Other Current Assets
70
73
86
143
122
147
Total Current Assets
1,061
1,669
1,545
2,727
2,037
1,724
Net Property, Plant & Equipment
3,429
3,215
2,987
2,854
2,637
2,453
Total Investments and Advances
122
143
186
581
625
1,085
Intangible Assets
518
468
420
373
199
167
Other Assets
77
83
69
22
19
21
Total Assets
5,487
5,857
5,435
6,785
5,746
5,678
ST Debt & Current Portion LT Debt
278
78
300
680
378
Accounts Payable
11
33
12
27
41
Other Current Liabilities
108
92
116
111
192
Total Current Liabilities
397
203
428
818
611
Long-Term Debt
1,843
1,180
1,300
2,824
2,739
Deferred Taxes
279
280
228
228
228
Other Liabilities
8
7
21
63
61
Total Liabilities
2,249
1,390
1,750
3,705
3,412
Common Equity (Total)
3,237
4,198
3,436
2,863
2,095
Total Shareholders' Equity
3,237
4,198
3,436
2,863
2,095
Total Equity
3,237
4,467
3,685
3,080
2,334
Liabilities & Shareholders' Equity
5,487
5,857
5,435
6,785
5,746
Accumulated Minority Interest
-
270
249
216
240

About Adimmune

View Profile
Address
No. 3, Sec. 1, Tanxing Road
Taichung TX 427 23
Taiwan
Employees -
Website http://www.adimmune.com.tw
Updated 07/08/2019
Adimmune Corp. engages in the development, manufacture, and distribution of human vaccine. Its products include seasonal influenza vaccine, Japanese encephalitis vaccine, and tetanus toxoid alum precipitated. The company also provides fill and finish services, testing/analysis services, quality assurance courses, and consulting services.